IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Encore Medical, Inc.
Encore Medical is a structural heart device company dedicated to the transcatheter closure of certain cardiac defects.We develop, manufacture, and market septal occlusion products, which are small, implantable devices delivered through a catheter inserted into a major blood vessel to permanently repair certain cardiac defects.
Our devices include patented technology that has been in use extensively outside of the U.S.
Procedures are performed in a cardiac catheterization lab and reduce the need for open heart surgery or a lifetime of drug therapy, which are currently the primary alternative methods for treating these defects.
We have developed devices capable of providing effective, nonsurgical methods of correcting a variety of cardiac defects in both adults and children.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Key valuation ratios and metrics
Balance sheet strength and liquidity
Margins and return on capital
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| FWP | Apr 9, 2026 | Free Writing Prospectus |
| S-1/A | Apr 6, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| FWP | Apr 3, 2026 | Free Writing Prospectus |
| FWP | Mar 25, 2026 | Free Writing Prospectus |
| S-1/A | Mar 24, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | Mar 3, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | Dec 30, 2025 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Sep 15, 2025 | General form for registration of securities under the Securities Act of 1933 |
| D | May 3, 2022 | Notice of Exempt Offering of Securities |
| D | Dec 28, 2020 | Notice of Exempt Offering of Securities |
Contact and headquarters details
Key executives and officers
Joseph A. Marino
Chairman of the Board of Directors, President and Chief Executive Officer
Peter M. Buonomo
Senior Vice President, Director
Scott S. Robinson
Treasurer
Timothy G. Laske, PhD
Director
Christopher J. Turnbull
Director
Todd C. Johnson
Director

Issue Size
$15.00M
Price Range
$5.00
Shares
9.74M o/s · 3M offered
Listing Price
$5.00
Sector
Healthcare